H1 Melanoma Pipeline Products and Key Players Pipeline Review Market Research Report
Melanoma – Pipeline Market Review, H1 2017 report provides an overview of the Melanoma pipeline landscape. The Melanoma pipeline guide encapsulates all the dormant and discontinued pipeline projects.
July 11, 2017 /MarketersMedia/ —
RnRMarketResearch.com include Melanoma – Pipeline Review, H1 2017 is new Oncology report. It is complete research and development history and latest news and press releases.
Melanoma Pipeline report has 246 Company Profiles and 11 Figures, Spread across 1779 Pages Report Available at http://www.rnrmarketresearch.com/melanoma-pipeline-review-h1-2017-market-report.html .
Melanoma Pipeline key players are 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc, Abivax SA, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Affichem SA, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alethia Biotherapeutics Inc, Alkermes Plc, Altor BioScience Corp, Amgen Inc, Anavex Life Sciences Corp, Angimmune LLC, Antibe Therapeutics Inc, Antigen Express Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, Apogenix GmbH, Aposense Ltd, Aptose Biosciences Inc, ARMO Biosciences Inc, Array BioPharma Inc, Asana BioSciences LLC, Astellas Pharma Inc more..
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1126469
Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively.
Discount Available at http://www.rnrmarketresearch.com/contacts/discount?rname=1126469
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
List of Figures
Number of Products under Development for Melanoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
Related Report:
Uveal Melanoma – Pipeline Review, H1 2017 : Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celldex Therapeutics Inc, Cleveland BioLabs Inc, Delcath Systems Inc, Eli Lilly and Company, Iconic Therapeutics Inc, Immunocore Ltd, Lion Biotechnologies Inc, Navigen Inc, Novartis AG, PEP-Therapy SAS, Pfizer Inc, Polaris Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Syndax Pharmaceuticals Inc.
About Us:
RnRMarketResearch.com is your one stop market research and industry analysis reports’ library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.
Contact Info:
Name: Ritesh Tiwari
Email: sales@rnrmarketresearch.com
Organization: RnRMarketResearch.com
For more information, please visit http://www.rnrmarketresearch.com/melanoma-pipeline-review-h1-2017-market-report.html
Source: MarketersMedia
Release ID: 216507
Copyright © 1999-2013 SproutNews.com
